You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTyloxapol
Accession NumberDB06439
TypeSmall Molecule
GroupsApproved, Investigational
Description

Tyloxapol is a non-ionic detergent often used as a surfactant.

Structure
Thumb
SynonymsNot Available
SaltsNot Available
Brand names
NameCompany
AlevaireNot Available
Brand mixturesNot Available
Categories
CAS number25301-02-4
WeightAverage:
Monoisotopic:
Chemical FormulaNot Available
InChI KeyUTFVNNPSMPINLE-UHFFFAOYSA-N
InChI
InChI=1S/C51H80O6/c1-35-25-41(50(13,14)33-47(5,6)7)29-37(44(35)56-23-20-53)27-39-31-42(51(15,16)34-48(8,9)10)30-38(45(39)57-24-21-54)26-36-28-40(17-18-43(36)55-22-19-52)49(11,12)32-46(2,3)4/h17-18,25,28-31,52-54H,19-24,26-27,32-34H2,1-16H3
IUPAC Name
SMILES
Mass SpecNot Available
Taxonomy
KingdomNot Available
SuperclassNot Available
ClassNot Available
SubclassNot Available
Direct parentNot Available
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationUsed as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.
PharmacodynamicsIt is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions. Tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.
Mechanism of actionTyloxapol, when injected IP, blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. It has also been shown to be inhibitor of lipoprotein lipase, thus preventing triglyceride uptake.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAcute oral LD50 in 1000 mg/kg in mouse and 5000 mg/kg in rat.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption Not Available Not Available
Blood Brain Barrier Not Available Not Available
Caco-2 permeable Not Available Not Available
P-glycoprotein substrate Not Available Not Available
P-glycoprotein inhibitor I Not Available Not Available
P-glycoprotein inhibitor II Not Available Not Available
Renal organic cation transporter Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 1A2 substrate Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 2C19 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 inhibitory promiscuity Not Available Not Available
Ames test Not Available Not Available
Carcinogenicity Not Available Not Available
Biodegradation Not Available Not Available
Rat acute toxicity Not Available Not applicable
hERG inhibition (predictor I) Not Available Not Available
hERG inhibition (predictor II) Not Available Not Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Enuclene drops0.69USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Stateliquid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Spectra
SpectraNot Available
References
Synthesis ReferenceNot Available
General Reference
  1. Bhatia AJ, Wade GN: Effects of pregnancy and ovarian steroids on fatty acid synthesis and uptake in Syrian hamsters. Am J Physiol. 1991 Jan;260(1 Pt 2):R153-8. Pubmed
External Links
ResourceLink
KEGG DrugD03261
ChemSpider11052515
Therapeutic Targets DatabaseDCL000254
PharmGKBPA164743726
Drugs.comhttp://www.drugs.com/ingredient/tyloxapol.html
WikipediaTyloxapol
ATC CodesR05CA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(73.4 KB)
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Lipoprotein lipase

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Lipoprotein lipase P06858 Details

References:

  1. Levine S, Saltzman A: A procedure for inducing sustained hyperlipemia in rats by administration of a surfactant. J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):224-6. Epub 2006 Jun 3. Pubmed
  2. Rodrigues B, Braun JE, Spooner M, Severson DL: Regulation of lipoprotein lipase activity in cardiac myocytes from control and diabetic rat hearts by plasma lipids. Can J Physiol Pharmacol. 1992 Sep;70(9):1271-9. Pubmed
  3. Sato K, Akiba Y, Horiguchi M: Species differences between chickens and rats in chemical properties of adipose tissue lipoprotein lipase. Comp Biochem Physiol A Physiol. 1997 Nov;118(3):855-8. Pubmed

Comments
comments powered by Disqus
Drug created on March 19, 2008 10:33 / Updated on October 03, 2013 23:48